Main Conference Day 3 - PT (Pacific Time, GMT-08:00)
Main Conference Day 3 - PT (Pacific Time, GMT-08:00)
6:30am - 7:15am45 mins
Scientific Breakfast Briefing #1
Sunrise Yoga: Wellness Event - Rancho Santa Fe, Lobby Level (45 minutes)
6:30am - 7:15am45 mins
Scientific Breakfast Briefing #2
Sunrise Yoga: Wellness Event - Rancho Santa Fe, Lobby Level (45 minutes)
7:15am - 7:30am15 mins
Scientific Breakfast Briefing #1
Registration
7:15am - 7:30am15 mins
Scientific Breakfast Briefing #2
Registration
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #1
VHH and VLL Discovery Using ATX Transgenic Animals and Yeast Displayed Libraries
- Nikolai Suslov - VP, Waltham Site Lead, Antibody Division, Alloy Therapeutics
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #2
Available for Sponsorship
8:10am - 8:15am5 mins
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs
Co-Chairs’ Remarks
- Udaya Rangaswamy, Ph.D. - Senior Scientist, Rondo therapeutics
- Eric Smith - Executive Director - Bispecifics, Regeneron Pharmaceuticals
8:10am - 8:15am5 mins
Track 2: Engineering Antibody Interfaces: Unlocking New Biology
Co-Chairs’ Remarks
- John Desjarlais, PhD - Chief Scientific Officer, Xencor, Inc.
- Greg Lazar, Ph.D. - Co-Founder and Chief Scientific Officer, Dualitas Therapeutics
8:15am - 8:45am30 mins
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs
Novel Multispecific Antibodies for Cancer and Immunological Diseases
- John Mascola - Chief Scientific Officer, ModeX Therapeutics
8:15am - 8:45am30 mins
Track 2: Engineering Antibody Interfaces: Unlocking New Biology
A New Homotypic Interface Expands Anti-Malarial Antibody Recognition Breadth
- Jihwan Chun - Postdoctoral Research Fellow, Harvard University
8:45am - 9:15am30 mins
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs
Engineering Trispecific T Cell Engagers (TriTCEs) For Optimal Activity and Developability
- Genevieve Desjardins - Associate Director in Protein Engineering, Zymeworks Inc
8:45am - 9:15am30 mins
Track 2: Engineering Antibody Interfaces: Unlocking New Biology
From Nanobody Repertoires to Programmable Medicines: Proteomics, AF3-TurboAb, and Multivalent Design
- Yi Shi, Ph.D. - Professor, University of Pittsburgh, School of Medicine
9:15am - 9:45am30 mins
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs
Multispecific Antibodies: Design, Function, and Developability
- Stefan Warmuth, PhD - SVP, Head Technology and CMC, Numab Therapeutics AG
9:15am - 9:45am30 mins
Track 2: Engineering Antibody Interfaces: Unlocking New Biology
XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life
- Gregory Moore, Ph.D. - Director, Protein Engineering, Xencor
9:45am - 10:30am45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
Networking Refreshment Break
10:00am - 10:10am10 mins
Technology Showcase Presentations in the Exhibit Hall
Technology Showcase TBA
10:30am - 11:00am30 mins
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs
CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index
- Xiuling Li - Director, AstraZeneca
10:30am - 11:00am30 mins
Track 2: Engineering Antibody Interfaces: Unlocking New Biology
MP0632: A Logic-Gated Switch-DARPin T Cell Engager with CD2 Co-Stimulation for Enhanced Safety and Efficacy in MSLN/EpCAM Co-Expressing Solid Tumors
- Martin Steegmaier, Ph.D. - Chief Scientific Officer, Molecular Partners AG
11:00am - 11:30am30 mins
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs
TIE-ADC™: A Bispecific ADC Platform Eliminating Cancer Cells and Tumor Immunosuppressor Cells to Enhance Anti-Tumor Immunity
- Shiva Bhowmik - President & CEO, Trio Pharmaceuticals
11:00am - 11:30am30 mins
Track 2: Engineering Antibody Interfaces: Unlocking New Biology
How Nanoscale Spatial Organization Determines Therapeutic Antibody Function
- Isabelle Pachmayr - PhD Student, Max Planck Institute of Biochemistry
11:30am - 12:00pm30 mins
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs
Building Moats around Multispecifics: Technical Strategies for High-Value Antibody Patent Portfolios
- Benjamin Pelletier - Co-Chair, Haynes and Boone
11:30am - 12:00pm30 mins
Track 2: Engineering Antibody Interfaces: Unlocking New Biology
Enabling Polyclonal Antibody Production through Fc-engineering of Mutual Exclusive CH3 Interfaces
- Aran Labrijn, PhD - Director, Antibody Research and Technologies, Genmab
12:00pm - 12:30pm30 mins
Scientific Briefing 1
Scientific Briefing: Available for Sponsorship
12:00pm - 12:30pm30 mins
Scientific Briefing 2
Scientific Briefing: Available for Sponsorship
12:00pm - 12:30pm30 mins
Scientific Briefing 3
Scientific Briefing- Available for Sponsorship
12:00pm - 12:30pm30 mins
Scientific Briefing 4
Scientific Briefing- Available for Sponsorship
12:00pm - 12:30pm30 mins
Scientific Briefing 5
Scientific Briefing- Available for Sponsorship
12:30pm - 2:10pm100 mins
Networking Luncheon, Exhibit and Poster Viewing
Networking Luncheon, Last Chance for Exhibit and Poster Viewing
2:10pm - 2:15pm5 mins
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Co-Chairs' Remarks
- Vaishali Kapoor - Assistant Professor, Radiation Oncology, Washington University School of Medicine
- Krista Kinneer - Director, Oncology Translational Medicine, AstraZeneca
2:10pm - 2:15pm5 mins
Track 2: Engineering Innovative Functionality into Antibody Domains
Chairs’ Remarks
- Paul Parren, PhD - Founder and CSO, Gyes BV
- David Lutje Hulsik, PhD - Senior Director Bioinformatics and Protein Engineering, Gyes BV
2:15pm - 2:45pm30 mins
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Expanding the Toolbox: Non-natural Amino Acids Enable Development of a CD30 Dual-payload ADC
- Megan Rice - Associate Principal Scientist, AstraZeneca
2:15pm - 2:45pm30 mins
Track 2: Engineering Innovative Functionality into Antibody Domains
The Bispecific and Multispecific Revolution in Antibody Therapeutics for Autoimmune and Inflammatory Diseases
- Sigrid Cornelis - Distinguished Scientist, Sanofi
2:45pm - 3:15pm30 mins
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Antigen-Independent Antitumor Activity of ONM-421, a pH-Responsive Polymer-Drug Conjugate Delivering MMAE to Solid Tumors
- Tian Zhao, PhD - Vice President of R&D, OncoNano Medicine Inc.
2:45pm - 3:15pm30 mins
Track 2: Engineering Innovative Functionality into Antibody Domains
FcyRIIB selective antigen-Fc fusion proteins enable selective neutralization, clearance, and B-cell inhibition of pathogenic autoantibodies
- Dario Gutierrez, PhD - Founder and Chief Scientific Officer, Merida Biosciences
3:15pm - 3:45pm30 mins
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
DLL3 Antibody-Based Radiotheranostics: From ImmunoPET to Targeted Radioligand Therapy
- Salomon Tendler, MD, PhD - Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
3:15pm - 3:45pm30 mins
Track 2: Engineering Innovative Functionality into Antibody Domains
MPACT: Engineering the Fc-FcγR Interface for Plug-and-Play, Mixed-Valency Multispecific Antibodies
- John Williams - Professor, Cancer Biology and Molecular Medicine, City of Hope
3:45pm - 4:15pm30 mins
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Networking Refreshment Break
3:45pm - 4:15pm30 mins
Track 2: Engineering Innovative Functionality into Antibody Domains
Networking Refreshment Break
4:15pm - 4:45pm30 mins
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Turning up the Heat: Radioimmunoconjugates for Targeted Radiation Therapy
- Anna Wu, PhD - Chair and Professor, Department of Immunology and Theranostics, City of Hope
4:15pm - 4:45pm30 mins
Track 2: Engineering Innovative Functionality into Antibody Domains
A Novel Antibody Approach to Pan-subclass IgG Reduction
- Ibo Janssens - Senior Scientist, Argenx
4:45pm - 5:15pm30 mins
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
uPAR Targeting Cytotoxic Antibody Drug Conjugates Selectively Deplete Proinflammatory Myeloid Cells for Autoimmune Indications
- Grace Mortenson - Associate Principal Scientist, Merck Research Labs
4:45pm - 5:15pm30 mins
Track 2: Engineering Innovative Functionality into Antibody Domains
Expanding the Fc Functional Spectrum: A Diverse Repertoire of Novel Fc Variants for Enhanced Potency, Complete Effector Silencing, Extended Persistence, and Accelerated Pathogenic IgG Clearance
- Sang Taek Jung, PhD - Associate Professor, Seoul National University
5:15pm - 5:45pm30 mins
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Novel, Next-generation ADCs for Autoimmune and Inflammatory Diseases
- Jerome Boyd-Kirkup - Co-Founder & CSO, Hummingbird Bioscience, Singapore
5:15pm - 5:45pm30 mins
Track 2: Engineering Innovative Functionality into Antibody Domains
Machine Learning and the Use of Computational-experimental Workflows to Study Antibody Structure-function Relationships
- Franca Fraternali, PhD - Head of Research Department, University College London
5:45pm - 5:50pm5 mins
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Close of Conference
5:45pm - 5:50pm5 mins
Track 2: Engineering Innovative Functionality into Antibody Domains
Close of Conference
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。